Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TITANIA: Tozorakimab in symptomatic COPD with exacerbation history
CTR20221338Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tozorakimab in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Jun 2022; status: completed.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20221338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221338.